Andrew Perlman

Guide Therapeutics, Inc. develops biophotonic technology platform for the early detection of disease that leads to cancer. The company was founded by James Dahlman and Cory Sago and is headquartered in Tucker, GA.

Jetti Resources LLC is a technology-driven natural resources company. The company is based in Boulder, CO and has subsidiaries in Canada. The company was founded by Andrew Perlman and the CEO is Mike Outwin.

Sirona Medical, Inc. develops medical image software and provides health care services . The company was founded in 2018 and is headquartered in San Francisco, CA.

AMP Americas LLC operates as an integrated transport company. The company was founded by Nathan Laurellis and Steve Josephs in 2011 and is headquartered in Chicago, IL.

AltaRock Energy, Inc. develops and commercializes geothermal technology. It develops and commercializes geothermal technology to produce clean and renewable power. The company was founded by Robert Banack, Aaron H. Mandell and Susan Petty in 2007 and is headquartered in Seattle, WA.

Zafgen, Inc. is a biopharmaceutical company, which engages in the development of novel therapies for patients affected by complex metabolic diseases. It focuses on the study of MetAP2 inhibitors in both common and rare metabolic disorders. The firm also advancing programs for type 2 diabetes, Prader-Willi syndrome, and liver diseases. The company was founded on November 22, 2005 and is headquartered in Boston, MA.

Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA.

KittyHawk Ventures LLC (KittyHawk Ventures) is a venture capital firm founded in 2015 by Will Weisman. The firm is headquartered in Santa Monica, California.

Invicta Medical, Inc. operates as a medical technology company that develops wearable device for treatment of sleep apnea and snoring. Its device detects and treats disturbed breathing through electrical stimulation. The company was founded by Steven T. Kent and Harold Kent in 2013 and is headquartered in Portola Valley, CA.